脑肿瘤活检后出血并发症:基于更安全活检靶点与技术的风险降低策略
该回顾性研究纳入2011—2020年208例接受活检的脑肿瘤(恶性淋巴瘤或胶质瘤)连续患者,评估活检后出血的相关因素。术后全部出血和症状性出血分别发生于21.6%和9.6%的患者。多因素分析显示穿刺针活检、WHO III/IV级胶质瘤及多发病灶与出血独立相关;术前MRI肿瘤内大量微出血、活检部位微出血及高相对脑血流亦显著相关。作者据此提出优先选择可充分止血的活检技术、对高危病例更仔细止血、多候选靶点时选择低rCBF且无微出血区域等预防措施。
要点
- 穿刺针活检较开放或内镜活检显著增加全部及症状性出血风险。
- WHO III/IV级胶质瘤和多发病灶是术后出血的独立危险因素。
- 术前MRI肿瘤内大量微出血、活检部位微出血及高rCBF与出血显著相关。
核心结论
- 作者推荐优先考虑可充分止血的活检技术,对疑似WHO III/IV级胶质瘤、多发病灶及肿瘤内大量微出血者更仔细止血,多候选靶点时选择低rCBF且无微出血区域。
研究设计与样本
- 回顾性收集2011—2020年208例连续脑肿瘤(恶性淋巴瘤或胶质瘤)活检患者的数据,评估术前MRI肿瘤内微出血及活检部位相对脑/肿瘤血流量等因素。
主要发现
- 术后全部出血发生于21.6%的患者,症状性出血发生于9.6%的患者。
- 单因素分析中,与可充分止血操作的技术(即开放和内镜活检)相比,穿刺针活检与全部及症状性出血风险显著相关。
- 多因素分析显示,穿刺针活检和WHO III/IV级胶质瘤与术后全部及症状性出血显著相关;多发病灶也是症状性出血的独立危险因素。
- 术前MRI上肿瘤内大量微出血、活检部位微出血以及高rCBF均与术后全部及症状性出血显著相关。
临床怎么用
- 作者推荐优先考虑可充分止血操作的活检技术。
- 作者建议对疑似WHO III/IV级胶质瘤、多发病灶及肿瘤内大量微出血的病例更仔细止血。
- 作者建议若存在多个候选活检部位,选择rCBF较低且无微出血的区域作为活检靶点。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Brain tumor biopsies are essential for pathologic diagnosis. However, hemorrhagic complications after biopsies may occur, leading to suboptimal outcomes. This study aimed to evaluate the associated factors of hemorrhagic complications after brain tumor biopsies and propose countermeasures. METHODS: We retrospectively collected data on 208 consecutive patients with brain tumors (malignant lymphoma or glioma) who underwent a biopsy from 2011-2020. We evaluated factors and microbleeds (MBs) in the tumor plus relative cerebral/tumoral blood flow (rCBF) at the biopsy site on preoperative magnetic resonance imaging (MRI). RESULTS: Postoperative all and symptomatic hemorrhage occurred in 21.6% and 9.6% of patients. In univariate analysis, a needle biopsy was significantly associated with the risk of all and symptomatic hemorrhages compared to techniques that allow adequate hemostatic manipulation (i.e., open and endoscopic biopsies). Multivariate analyses revealed that a needle biopsy and gliomas of World Health Organization (WHO) grade III/IV were significantly associated with postoperative all and symptomatic hemorrhages. Multiple lesions were also an independent risk factor for symptomatic hemorrhages. On preoperative MRI, abundant MBs in the tumor and MBs at the biopsy sites, in addition to high rCBF, were significantly associated with postoperative all and symptomatic hemorrhages. CONCLUSIONS: We recommend the following measures to prevent hemorrhagic complications: consider biopsy techniques that allow adequate hemostatic manipulation preferentially; perform more careful hemostasis in cases of suspected gliomas of WHO grade III/IV, multiple lesions, and abundant MBs in the tumors; and, if there are multiple candidate biopsy sites, select areas with lower rCBF and no MBs as a biopsy target.
引用
- Sugii N, Matsuda M, Tsurubuchi T, et al. Hemorrhagic Complications After Brain Tumor Biopsy: Risk-Reduction Strategies Based on Safer Biopsy Targets and Techniques. World Neurosurg. 2023. PMID: 37207726. doi:10.1016/j.wneu.2023.05.046
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。